Avenue Therapeutics, Inc. (ATXI)

US — Healthcare Sector
Peers: HOTH  REVB  NRBO  VRAX  PBLA  PALI  QNRX  CFRX  ALLR  CNSP  WINT    KRBP  BDRX 

Automate Your Wheel Strategy on ATXI

With Tiblio's Option Bot, you can configure your own wheel strategy including ATXI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ATXI
  • Rev/Share 0.0
  • Book/Share 0.785
  • PB 0.2032
  • Debt/Equity 0.0
  • CurrentRatio 2.775
  • ROIC -4.228

 

  • MktCap 764382.0
  • FreeCF/Share -2.3872
  • PFCF -0.1078
  • PE -0.0522
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -3.9933

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Avenue Therapeutics, Inc. (ATXI)

  • IPO Date 2017-06-27
  • Website https://www.avenuetx.com
  • Industry Biotechnology
  • CEO Dr. Alexandra MacLean M.D.
  • Employees 2
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.